• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

Shark Bites: FDA Delay Is Creating a Buying Opportunity in Beyond Air

There was over $2 million in insider buying earlier in the year so management appears to be optimistic.
By JAMES "REV SHARK" DEPORRE
Oct 04, 2021 | 01:11 PM EDT
Stocks quotes in this article: XAIR

I have been following Beyond Air (XAIR) for a few months now and am using recent weakness to rebuild a position that I had reduced into strength. Beyond Air is a clinical-stage biotechnology company that uses medical-grade nitric oxide (NO) to treat lung conditions. The LungFit system uses proprietary technology to generate NO from ambient air. A separate unique delivery system allows for the administration of ultra-high NO concentrations directly to solid tumors. LungFit PH allows NO to be administered to ventilated patients in the hospital without using cumbersome cylinder systems and is administered at home.

XAIR is waiting for the FDA to grant premarket approval (PMA) of its application for LungFit PH to treat persistent pulmonary hypertension in newborn infants (PPHN). The company expects a decision in the fourth quarter. The decision was expected in the third quarter but has been pushed back. The company has completed the necessary Stage 1 Assessment and now the FDA is undergoing inspection of the manufacturing process.

Nitros Oxide is already well known to be an effective treatment for a variety of conditions. What XAIR is offering is a much more convenient and effective delivery process. The hurdle for FDA approval is much lower than if this was a new drug.

XAIR also expects two other milestones before the end of the year. Preliminary results from the LungFit GO Nontuberculous Mycobacteria (NTM) lung infection at-home pilot study are expected, and the company's solid tumor program should receive regulatory clearance for human trials by year's end.

There was over $2 million in insider buying earlier in the year so management appears to be optimistic. In addition, XAIR has coverage from four analysts in the last three months and all four have 'buy' recommendations. Matthew Kaplan of Ladenburg has a $17 target and recently stated: "We remain confident that Beyond Air has set itself up to execute its timeline for commercial launch and label expansion. We believe the upcoming milestones could serve as significant potential catalysts for the stock."

The stock recently topped out on September 21 when management announced that FDA approval had been pushed back. Approval could come at any time and management has made it clear that it expects it to hit this quarter.

I've added to my position today and will be looking for further entry points.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, James "Rev Shark" DePorre was Long XAIR.

TAGS: Investing | Stocks | Technical Analysis | Trading | Biotechnology

More from Investing

Stay Guarded Amid Rally's Rotation

James "Rev Shark" DePorre
May 23, 2022 4:41 PM EDT

Stocks spin, and that makes the market picture rather murky.

Dare I Recommend a Retail Name Like American Eagle Outfitters?

Bruce Kamich
May 23, 2022 3:15 PM EDT

Let's check out the charts.

Look for General Motors Shares to Restart Their Uptrend

Bruce Kamich
May 23, 2022 2:10 PM EDT

Why aggressive traders could get behind the GM wheel again.

Alibaba Is Sold out on the Downside

Bruce Kamich
May 23, 2022 1:26 PM EDT

China at a bearish extreme is an opportunity.

It 'Bears' Repeating: Tune Out the Noise!

Bob Lang
May 23, 2022 1:16 PM EDT

The noise around the markets is loud, distracting and sometimes obnoxious, but if you listen to it, you'll end up making poor decisions.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 02:24 PM EDT PAUL PRICE

    An Interesting Chart

    I'm betting heavily that stocks will be way up aga...
  • 10:10 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    "Market Timing for Dummies"
  • 01:44 PM EDT STEPHEN GUILFOYLE

    Stocks Under $10 Portfolio

    We're making a series of trades here.
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login